Latest Reports

The “2024 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success. 

This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.

The “2024 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2029 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.

Market Scope has published the Ophthalmic Market Perspectives (OMP) newsletter for more than 20 years. The newsletter provides the latest business information that is shaping ophthalmic markets and professions. Our articles explore new technologies and company developments. We offer opinions on issues facing the industry. We also analyze and chart quarterly industry data, and we forecast market performance over time.

The “2024 United States Cataract Atlas” provides a geographic analysis of the conventional and premium cataract surgery opportunity in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index™ Analysis examines market potential and provides a benchmark against other metros. The atlas offers strategic insights into the top potential markets in the US, which companies often use throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives.

The “2024 United States Refractive Atlas” provides a geographic analysis of the US refractive market in 85 metropolitan areas. Market Scope’s MedOp Index™ Analysis is used to identify the potential for refractive surgery and considers many factors for each geography, including:  population age distribution, refractive error, income/buying power, overall health, education level, and location of refractive surgeons and LVC centers. High-opportunity populations and benchmarking comparisons are provided for each metropolitan area. Additionally, the atlas provides a comprehensive directory of all US practices offering refractive surgery. Market Scope also offers customization of atlas data to align with sales territories or specific geographic areas.

The “Ophthalmic Deals Report” analyzes recent investments in ophthalmology and provides information for evaluation of the market value of various technologies, as evidenced by investment amounts and sales prices for new ophthalmic ventures.

This report covers recent investments in ophthalmic ventures, including venture capital, public offerings, licensing, milestone payments, sales of products and companies, and major borrowings. The report is designed for entrepreneurs, investors, venture capitalists, and companies looking to invest in the ophthalmic market—and companies looking to raise funds.

The “2024 Retinal Surgical Device Market Report” provides in-depth analysis of the global retinal device market, examining the market’s size and growth, as well as identifying important developments that may shape its future. The analysis focuses on the 2024 market and forecasts market growth and evolution through 2029. Additionally, 21 retina device companies are profiled, with discussion of their products, strategic market position, background, and outlook.

Market Scope’s "2023 Corneal Disease Model" offers extensive country-level prevalence data and five-year forecasts for nine corneal diseases for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

Market Scope’s "2023 Dry Eye Disease Model" offers extensive country-level prevalence data and five-year forecasts for 13 dry eye-related segments of the population by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

Market Scope’s "2023 Refractive Error Model" offers extensive country-level prevalence data and five-year forecasts for five refractive error categories by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.